Category
Tafamidis
CAS Number
1395964-06-3
Molecular Formula
C₁₅H₉Cl₂NO₃
Molecular Weight
322.14 g/mol
Synonym

2-(3,5-dichlorphenyl)-6-benzoxazolecarboxylic acid methyl ester; Methyl 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate; 6-Benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)-, methyl ester; Methyl 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate

Keywords
Pharmaceutical Standards
Metabolites.
Impurities
slide.1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Tafamidis Impurity 6 is a process-related impurity identified during the synthesis or degradation of the medication Tafamidis, which is used for the treatment of transthyretin amyloidosis. It may originate from specific side reactions, intermediate transformations, or minor by-products formed during manufacturing or storage. This impurity is typically monitored and controlled using validated analytical methods such as HPLC or LC–MS to ensure the drug substance complies with regulatory quality and safety standards.